Global Poliomyelitis Vaccine in Dragee Candy Market Size By Type (Viruses I, Viruses ��), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Poliomyelitis Vaccine in Dragee Candy Market was valued at USD 1.3 billion in 2023 and is anticipated to surpass USD 2.8 billion by 2031, expanding at a CAGR of 10.2% during the forecast period from 2023 to 2031. The market is witnessing rapid growth due to increasing global immunization campaigns, innovative vaccine delivery methods targeting pediatric populations, and rising demand for needle-free, child-friendly vaccine formats. Dragee candy formulations, offering a palatable and easy-to-administer solution, are increasingly being adopted to combat vaccine hesitancy among children and caregivers, especially in developing countries.

Drivers:

1. Global Immunization Initiatives:

Programs such as the WHO’s Global Polio Eradication Initiative (GPEI) are significantly accelerating the demand for accessible vaccine formats. Dragee candy vaccines offer an attractive solution for oral administration, especially in remote or underserved regions.

2. Rise in Pediatric Vaccine Compliance:

The child-friendly taste and form factor of dragee candy vaccines reduce resistance and improve adherence to immunization schedules, increasing their adoption by healthcare providers and caregivers.

3. Needle-Free Delivery Innovation:

The global trend toward pain-free, non-invasive drug delivery is driving interest in oral vaccine alternatives. Dragee candy formats align well with this trend, improving patient comfort and minimizing logistical barriers like cold-chain dependency.

Restraints:

1. Limited Regulatory Approvals:

The novelty of dragee candy vaccines means that many regions lack clear regulatory pathways, delaying product rollouts and acceptance in national immunization programs.

2. Production and Stability Challenges:

Ensuring antigen stability and bioavailability in a candy-based matrix presents technical challenges, particularly for large-scale production in tropical climates.

Opportunity:

1. Expansion in Emerging Economies:

With vast pediatric populations and high unmet immunization needs, countries across Asia, Africa, and Latin America represent untapped markets for innovative vaccine formats like dragee candies.

2. Integration into School and Outreach Programs:

Oral candy vaccines are ideal for mass administration in schools and rural outreach campaigns, offering scalable solutions that require minimal medical infrastructure.

Market by System Type Insights:

In 2023, the Live Attenuated Vaccine in Dragee Form segment accounted for the largest share of the market. These formulations are favored for their proven efficacy, oral compatibility, and historical use in eradication programs. However, the Inactivated Vaccine in Candy Matrix segment is expected to grow at a faster pace due to improved shelf-stability and lower risk of vaccine-derived poliovirus.

Market by End-use Insights:

The Public Immunization Program segment dominated in 2023, fueled by global health agency procurements and national vaccination drives. Meanwhile, the Private Clinics & Pharmacies segment is gaining traction in urban areas with higher healthcare spending, reflecting growing consumer demand for convenient immunization solutions.

Market by Regional Insights:

Asia-Pacific held the largest share of the market in 2023, driven by high birth rates, strong government-backed immunization efforts, and a large base of pharmaceutical manufacturing. Africa is poised for the highest growth rate due to international funding support, increasing health awareness, and initiatives aimed at eradicating polio in the last remaining endemic regions.

Competitive Scenario:

Key players operating in the Global Poliomyelitis Vaccine in Dragee Candy Market include:

Bharat Biotech

Sanofi S.A.

Sinovac Biotech Ltd.

Bio Farma

GlaxoSmithKline plc

Astellas Pharma Inc.

Inovio Pharmaceuticals

Vaxart Inc.

Cadila Pharmaceuticals

PT Bio Farma (Persero)

These companies are focusing on pediatric vaccine innovation, strategic global health partnerships, and manufacturing scale-ups to strengthen market presence.

Scope of Work – Global Poliomyelitis Vaccine in Dragee Candy Market

Key Market Developments:

2023: Bharat Biotech launched a temperature-stable oral polio vaccine in candy form for low-resource settings.

2024: GlaxoSmithKline collaborated with UNICEF to expand access to child-friendly oral vaccines in sub-Saharan Africa.

2025: Vaxart Inc. received WHO prequalification for its dragee candy poliomyelitis vaccine, enabling procurement for global campaigns.

FAQs:

1) What is the current market size of the Global Poliomyelitis Vaccine in Dragee Candy Market?

The market was valued at USD 1.3 billion in 2023.

2) What is the major growth driver of the Global Poliomyelitis Vaccine in Dragee Candy Market?

The major driver is the rising adoption of needle-free, child-friendly immunization formats to enhance pediatric compliance and accessibility.

3) Which is the largest region during the forecast period in the Global Poliomyelitis Vaccine in Dragee Candy Market?

Asia-Pacific is expected to remain the largest region due to high birth rates and active immunization initiatives.

4) Which segment accounted for the largest market share in Global Poliomyelitis Vaccine in Dragee Candy Market?

The Live Attenuated Vaccine in Dragee Form segment held the largest share in 2023.

5) Who are the key market players in the Global Poliomyelitis Vaccine in Dragee Candy Market?

Key players include Bharat Biotech, Sanofi, Sinovac, GSK, Bio Farma, and Vaxart Inc.